{"name":"Intarcia Therapeutics","slug":"intarcia-therapeutics","ticker":"","exchange":"","domain":"","description":"Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. It was founded in 1995 under the name \"BioMedicines\" and changed to its present name in 2004. In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOaG5oYmUxOXdlRFRRQXMydEc0emVSWXhMUV9CSmJmMUdMUkVKSElaZjlOQmRVeXBOU1lia3huTl90d2wtS2lVSVpYb0Z2eWdoSG5Mb2hDbURrOUFiTFRjMmlvNnFaSGFRazZOekVvb1c0ck5sMnJLYWZ4dHhaMFVVYW9qWU5HTGNZU194S0wtaw?oc=5","date":"2024-05-29","type":"pipeline","source":"drugdiscoverytrends.com","summary":"100 of the best-funded private healthcare and biotech companies - drugdiscoverytrends.com","headline":"100 of the best-funded private healthcare and biotech companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOQVRfaUoyeTMyUFZEd1A5d3Y3MGJDa0dIX0Jzb3JQUVhlTHFMdFRLSXJfT0xVSmNaTUNNRzZhbUQ5UGdOWlFjVkVsRTNmMW0yR3c4T0dreUtvWGhuT0duaWlsNlhXVXA2THl6anB4cEd6d0tZMXlYRk8zTFlIN2lnZHVZaw?oc=5","date":"2023-09-22","type":"regulatory","source":"pharmaphorum","summary":"FDA panel votes against Intarcia’s GLP-1 implant - pharmaphorum","headline":"FDA panel votes against Intarcia’s GLP-1 implant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOUHhaZDFSbmFXenRsNHp3OEM0Q19VLUwtZExhb2hDclU5bGxkVHRfa3BlR2N3TEdfdmlSb3R3dnpITExTMUtoWUFnTHBKdXBNREYwREZ2akQ0TXpxNUZ1b05YXzVManJnc2VmSHhsQmhHSjh0ZDdQQlBnNGpuNjZNbmdKWDdjX05zcS1wTnN6NF8?oc=5","date":"2023-09-21","type":"regulatory","source":"BioPharma Dive","summary":"Intarcia’s diabetes drug-device combo voted down again by FDA panel - BioPharma Dive","headline":"Intarcia’s diabetes drug-device combo voted down again by FDA panel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNMWEtOEVGU2k0cXMxMU04eWpXeV9yWHk4X0xhUGF1VmlsY1o3YnREdHRFUVppOERpTU9fSFpBRzFSaGN3SlQwZkJ5Qi1acUhiNlNkNElmZlRTakRYNWtPcFFfanFtWVJMcUtpNkVrakNHWkNkbDZSdEdieW8wakJZeDhQckNoQVk?oc=5","date":"2023-09-05","type":"pipeline","source":"Drug Delivery Business","summary":"GLP-1 startup i2o looks to revive diabetes drug-eluting implant from Intarcia - Drug Delivery Business","headline":"GLP-1 startup i2o looks to revive diabetes drug-eluting implant from Intarcia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOLVlxTE5HQVUxYWtSRUxxeVNyTkFWdm02YXE4NnBTaWljZlJYS3V0UWZsd0pFYnZ6dFI0YjBibkhUemlwQmNyUnVxa1ZYQ1hfNTQyRVJvYjRxbUg4OEs3c2xYdVZNTkFXbVEwbVR5bFNZVVpFUUpSNHlFb1ZvNUNNR25jX0ljTUh4OWw1TEQ1cC1Mb2M?oc=5","date":"2023-08-30","type":"deal","source":"BioPharma Dive","summary":"Intarcia, a former biotech unicorn, gets new life with startup deal - BioPharma Dive","headline":"Intarcia, a former biotech unicorn, gets new life with startup deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9NUXZaaHJfYnhIU2xsakh5SmtMa2o5VjV4MzhGdzB3dnprMW4yM0l4blBUUDJnLW5acG92NnI4a2NscXNTTWR5OU1RdkxESl9MNVVZTEtseEhKRkp3OE1mS0NabDhhOElQZURDeEFSU3ZHZzFzdkJVanl1TzR2Zw?oc=5","date":"2023-04-10","type":"pipeline","source":"Pharma Voice","summary":"Where one unicorn struggled, another biotech is aiming for a diabetes win - Pharma Voice","headline":"Where one unicorn struggled, another biotech is aiming for a diabetes win","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNU051V0tvbUpXaWRESFNxaE1GcG5YUVJrSDhLZXFFR3dCRlNNNU5CSjlyNnJCcVQ1eUFuc3BIWTR3WW9penZicHJ6TTZvS3FnYm1reFgtb19UTkx6Y3k4dnJJTjA3ZFgzX2N4Unh6R29jODNwcDlVMmVZRzFnTmdfUXdPQ2pZWXROd0JTOEJTbGpTRWJUeHVvLXRrbkRFaTVwU3lEOU9OMmdMLVN4eXBCUmVTT2ZhQ2k4TnJRS3VVMEI?oc=5","date":"2021-09-07","type":"regulatory","source":"Fierce Pharma","summary":"Intarcia faces FDA refusal to approve as push to get diabetes delivery system to market enters endgame - Fierce Pharma","headline":"Intarcia faces FDA refusal to approve as push to get diabetes delivery system to market enters endgame","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOMW5NMWVFbUF2emNPdi1wY3Nwbk5KQjFpSUo3QkhkRUhiMDRiOFhWSzJFRmJ5WExLT0FVcGRWSjNRSGhyQlFsNmhjY0hrZERzd1FSRldJWVd2a0EzOEYzUks1OEpfZXM4aVBidWpzR3h6RFdxR2xVT3lLdVBzUjgzVVVDTGhtSEZPSFJGSzJDVzNCeGRJeDZTSk42dGJvdjR4WGJ4M1YtbjJyNkdJSmtLU1JzalIxeGhGUUE?oc=5","date":"2020-11-23","type":"pipeline","source":"Mintz","summary":"Intarcia Secures Novel $300M Synthetic Royalty Financing with Equity Conversion Option at $5.5B - Mintz","headline":"Intarcia Secures Novel $300M Synthetic Royalty Financing with Equity Conversion Option at $5.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOUWVHbjFMR1NJRzR2MzdJSnNaMUw2VFN3ZFRlSnRqTVdLaU5IMG8xdTU0QmItdmRXb3dDTHZMQWt4VFdxUjBVUEpuVXZXV2RHaTdaa2hNbjE2QXlfeS10Y3VMZDFzUFhoS1lERUhRUTRvNlZheHpTN3RGYmZVQVljNDdQaHVIekhpVnNKSVlPTmNpVElRRlE?oc=5","date":"2018-04-02","type":"pipeline","source":"Fierce Biotech","summary":"Longtime Novartis executive takes the helm at Macrolide Pharma - Fierce Biotech","headline":"Longtime Novartis executive takes the helm at Macrolide Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNcGwycWdIVXRPek5VVFMteGpPSlBzWm9aTVE2Z1N0aW1GMFBaZ1V4ZktLNE0wNThRWjVXSUpZc1JrV2lORkZVSVAyRFM1TXR0bm9mRWJYTFdSNkxocjJqLTY5R2ZYRnB5YUZWdjJqSW1yQmNFcVg3QnhlbWY5VVEtV0NlMzM3YU1zY29qQUNjWHZJZU1ZWVZ1UEZpYU1sTWVvcmVPRFBQaXJCcnRFNU8wMWxTWWl3MlM3T2lON0xB?oc=5","date":"2015-09-30","type":"pipeline","source":"BioSpace","summary":"Intarcia CEO Kurt Graves Discusses Phoundry Acquisition and Future of Diabetes Treatment - BioSpace","headline":"Intarcia CEO Kurt Graves Discusses Phoundry Acquisition and Future of Diabetes Treatment","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2015-09-24","type":"deal","source":"PR Newswire","summary":"Intarcia Announces Acquisition of Phoundry Pharmaceuticals - Second Pipeline Deal of 2015 Secures Novel Peptide Therapeutics to Combine with ITCA 650 Targeting Next Gen Diabetes & Obesity Therapies - ","headline":"Intarcia Announces Acquisition of Phoundry Pharmaceuticals - Second Pipeline Deal of 2015 Secures Novel Peptide Therapeu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOWkpZZ0tmQ3hQMktEWlh1ZTdwUlJuT2hSZUw2WHhaQWxrZGkyNURsWFlrakVJMjVoamdtSm9ZYlR6aVlSQjAtQWFKSk5JaFlvY0pxcEhVU3lRT2dyVmhIY1ZDTUhRaTQzbkRKNFlYN2tuQllLU3lydnlqYnhYNTZRZGdoMlZOVFNfVFNXLWc3U1ZERUFJc1FvZ3ZJcHczekNna183d3BKTGw0TGhGU0lV?oc=5","date":"2014-08-06","type":"regulatory","source":"PMLiVE","summary":"Dr Sunita Zalani joins Intarcia Therapeutics as regulatory head - PMLiVE","headline":"Dr Sunita Zalani joins Intarcia Therapeutics as regulatory head","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}